Literature DB >> 25797123

Late gadolinium enhancement among survivors of sudden cardiac arrest.

Tomas G Neilan1, Hoshang Farhad2, Thomas Mayrhofer3, Ravi V Shah2, John A Dodson2, Siddique A Abbasi2, Stephan B Danik4, Daniel J Verdini3, Michifumi Tokuda2, Usha B Tedrow2, Michael Jerosch-Herold5, Udo Hoffmann3, Brian B Ghoshhajra3, William G Stevenson2, Raymond Y Kwong6.   

Abstract

OBJECTIVES: The aim of this study was to describe the role of contrast-enhanced cardiac magnetic resonance (CMR) in the workup of patients with aborted sudden cardiac arrest (SCA) and in the prediction of long-term outcomes.
BACKGROUND: Myocardial fibrosis is a key substrate for SCA, and late gadolinium enhancement (LGE) on a CMR study is a robust technique for imaging of myocardial fibrosis.
METHODS: We performed a retrospective review of all survivors of SCA who were referred for CMR studies and performed follow-up for the subsequent occurrence of an adverse event (death and appropriate defibrillator therapy).
RESULTS: After a workup that included a clinical history, electrocardiogram, echocardiography, and coronary angiogram, 137 patients underwent CMR for workup of aborted SCA (66% male; mean age 56 ± 11 years; left ventricular ejection fraction 43 ± 12%). The presenting arrhythmias were ventricular fibrillation (n = 105 [77%]) and ventricular tachycardia (n = 32 [23%]). Overall, LGE was found in 98 patients (71%), with an average extent of 9.9 ± 5% of the left ventricular myocardium. CMR imaging provided a diagnosis or an arrhythmic substrate in 104 patients (76%), including the presence of an infarct-pattern LGE in 60 patients (44%), noninfarct LGE in 21 (15%), active myocarditis in 14 (10%), hypertrophic cardiomyopathy in 3 (2%), sarcoidosis in 3, and arrhythmogenic cardiomyopathy in 3. In a median follow-up of 29 months (range 18 to 43 months), there were 63 events. In a multivariable analysis, the strongest predictors of recurrent events were the presence of LGE (adjusted hazard ratio: 6.7; 95% CI: 2.38 to 18.85; p < 0.001) and the extent of LGE (hazard ratio: 1.15; 95% CI: 1.11 to 1.19; p < 0.001).
CONCLUSIONS: Among patients with SCA, CMR with contrast identified LGE in 71% and provided a potential arrhythmic substrate in 76%. In follow-up, both the presence and extent of LGE identified a group at markedly increased risk of future adverse events.
Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cardiac magnetic resonance; implantable cardioverter-defibrillator; late gadolinium enhancement

Mesh:

Substances:

Year:  2015        PMID: 25797123      PMCID: PMC4785883          DOI: 10.1016/j.jcmg.2014.11.017

Source DB:  PubMed          Journal:  JACC Cardiovasc Imaging        ISSN: 1876-7591


  34 in total

1.  Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest : the Cardiac Arrest Study Hamburg (CASH).

Authors:  K H Kuck; R Cappato; J Siebels; R Rüppel
Journal:  Circulation       Date:  2000-08-15       Impact factor: 29.690

2.  Predicting sudden death risk for heart failure patients in the implantable cardioverter-defibrillator age.

Authors:  William G Stevenson; Laurence M Epstein
Journal:  Circulation       Date:  2003-02-04       Impact factor: 29.690

3.  The incidence, pattern, and prognostic value of left ventricular myocardial scar by late gadolinium enhancement in patients with atrial fibrillation .

Authors:  Tomas G Neilan; Ravi V Shah; Siddique A Abbasi; Hoshang Farhad; John D Groarke; John A Dodson; Otavio Coelho-Filho; Ciaran J McMullan; Bobak Heydari; Gregory F Michaud; Roy M John; Rob van der Geest; Michael L Steigner; Ron Blankstein; Michael Jerosch-Herold; Raymond Y Kwong
Journal:  J Am Coll Cardiol       Date:  2013-08-28       Impact factor: 24.094

4.  Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study.

Authors:  S J Connolly; A P Hallstrom; R Cappato; E B Schron; K H Kuck; D P Zipes; H L Greene; S Boczor; M Domanski; D Follmann; M Gent; R S Roberts
Journal:  Eur Heart J       Date:  2000-12       Impact factor: 29.983

5.  Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function.

Authors:  R J Kim; D S Fieno; T B Parrish; K Harris; E L Chen; O Simonetti; J Bundy; J P Finn; F J Klocke; R M Judd
Journal:  Circulation       Date:  1999-11-09       Impact factor: 29.690

6.  Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone.

Authors:  S J Connolly; M Gent; R S Roberts; P Dorian; D Roy; R S Sheldon; L B Mitchell; M S Green; G J Klein; B O'Brien
Journal:  Circulation       Date:  2000-03-21       Impact factor: 29.690

7.  The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction.

Authors:  R J Kim; E Wu; A Rafael; E L Chen; M A Parker; O Simonetti; F J Klocke; R O Bonow; R M Judd
Journal:  N Engl J Med       Date:  2000-11-16       Impact factor: 91.245

8.  Identification of reentry circuit sites during catheter mapping and radiofrequency ablation of ventricular tachycardia late after myocardial infarction.

Authors:  W G Stevenson; H Khan; P Sager; L A Saxon; H R Middlekauff; P D Natterson; I Wiener
Journal:  Circulation       Date:  1993-10       Impact factor: 29.690

9.  Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance.

Authors:  J A McCrohon; J C C Moon; S K Prasad; W J McKenna; C H Lorenz; A J S Coats; D J Pennell
Journal:  Circulation       Date:  2003-06-23       Impact factor: 29.690

10.  Analysis of implantable cardioverter defibrillator therapy in the Antiarrhythmics Versus Implantable Defibrillators (AVID) Trial.

Authors:  Richard C Klein; Merritt H Raitt; Bruce L Wilkoff; Karen J Beckman; James Coromilas; D George Wyse; Peter L Friedman; James B Martins; Andrew E Epstein; Alfred P Hallstrom; Robert B Ledingham; Karen M Belco; H Leon Greene
Journal:  J Cardiovasc Electrophysiol       Date:  2003-09
View more
  30 in total

Review 1.  Role of Imaging Techniques for Diagnosis, Prognosis and Management of Heart Failure Patients: Cardiac Magnetic Resonance.

Authors:  Jorge A Gonzalez; Christopher M Kramer
Journal:  Curr Heart Fail Rep       Date:  2015-08

2.  Predictors of subclinical systemic sclerosis primary heart involvement characterised by microvasculopathy and myocardial fibrosis.

Authors:  Raluca B Dumitru; Lesley-Anne Bissell; Bara Erhayiem; Graham Fent; Ananth Kidambi; Peter Swoboda; Giuseppina Abignano; Helena Donica; Agata Burska; John P Greenwood; John Biglands; Francesco Del Galdo; Sven Plein; Maya H Buch
Journal:  Rheumatology (Oxford)       Date:  2021-06-18       Impact factor: 7.580

3.  Heart failure and adverse heart failure outcomes among persons living with HIV in a US tertiary medical center.

Authors:  Raza M Alvi; Maryam Afshar; Anne M Neilan; Noor Tariq; Malek Hassan; Jaime Gerber; Magid Awadalla; Connor P Mulligan; Adam Rokicki; Virginia A Triant; Markella V Zanni; Tomas G Neilan
Journal:  Am Heart J       Date:  2019-01-11       Impact factor: 4.749

Review 4.  Heart Failure among People with HIV: Evolving Risks, Mechanisms, and Preventive Considerations.

Authors:  Mabel Toribio; Tomas G Neilan; Markella V Zanni
Journal:  Curr HIV/AIDS Rep       Date:  2019-10       Impact factor: 5.071

5.  The Risk for Sudden Cardiac Death Among Patients Living With Heart Failure and Human Immunodeficiency Virus.

Authors:  Raza M Alvi; Anne M Neilan; Noor Tariq; Malek O Hassan; Magid Awadalla; Lili Zhang; Maryam Afshar; Adam Rokicki; Connor P Mulligan; Virginia A Triant; Markella V Zanni; Tomas G Neilan
Journal:  JACC Heart Fail       Date:  2019-08-07       Impact factor: 12.035

6.  Sleep Apnea and Heart Failure With a Reduced Ejection Fraction Among Persons Living With Human Immunodeficiency Virus.

Authors:  Raza M Alvi; Noor Tariq; Atul Malhotra; Magid Awadalla; Virginia A Triant; Markella V Zanni; Tomas G Neilan
Journal:  Clin Infect Dis       Date:  2018-07-18       Impact factor: 9.079

7.  Myocarditis in Patients Treated With Immune Checkpoint Inhibitors.

Authors:  Syed S Mahmood; Michael G Fradley; Justine V Cohen; Anju Nohria; Kerry L Reynolds; Lucie M Heinzerling; Ryan J Sullivan; Rongras Damrongwatanasuk; Carol L Chen; Dipti Gupta; Michael C Kirchberger; Magid Awadalla; Malek Z O Hassan; Javid J Moslehi; Sachin P Shah; Sarju Ganatra; Paaladinesh Thavendiranathan; Donald P Lawrence; John D Groarke; Tomas G Neilan
Journal:  J Am Coll Cardiol       Date:  2018-03-19       Impact factor: 24.094

8.  Cardiac magnetic resonance imaging and electroanatomic voltage discordance in non-ischemic left ventricle ventricular tachycardia and premature ventricular depolarizations.

Authors:  Brian P Betensky; Wei Dong; Benjamin A D'Souza; Erica S Zado; Yuchi Han; Francis E Marchlinski
Journal:  J Interv Card Electrophysiol       Date:  2017-02-24       Impact factor: 1.900

Review 9.  Evaluation of Hypertrophic Cardiomyopathy: Newer Echo and MRI Approaches.

Authors:  Manhal Habib; Sara Hoss; Harry Rakowski
Journal:  Curr Cardiol Rep       Date:  2019-06-26       Impact factor: 2.931

10.  Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients With Immune Checkpoint Inhibitor-Associated Myocarditis.

Authors:  Paaladinesh Thavendiranathan; Lili Zhang; Amna Zafar; Zsofia D Drobni; Syed S Mahmood; Marcella Cabral; Magid Awadalla; Anju Nohria; Daniel A Zlotoff; Franck Thuny; Lucie M Heinzerling; Ana Barac; Ryan J Sullivan; Carol L Chen; Dipti Gupta; Michael C Kirchberger; Sarah E Hartmann; Jonathan W Weinsaft; Hannah K Gilman; Muhammad A Rizvi; Bojan Kovacina; Caroline Michel; Gagan Sahni; Ana González-Mansilla; Antonio Calles; Francisco Fernández-Avilés; Michael Mahmoudi; Kerry L Reynolds; Sarju Ganatra; Juan José Gavira; Nahikari Salterain González; Manuel García de Yébenes Castro; Raymond Y Kwong; Michael Jerosch-Herold; Otavio R Coelho-Filho; Jonathan Afilalo; Eduardo Zataraín-Nicolás; A John Baksi; Bernd J Wintersperger; Oscar Calvillo-Arguelles; Stephane Ederhy; Eric H Yang; Alexander R Lyon; Michael G Fradley; Tomas G Neilan
Journal:  J Am Coll Cardiol       Date:  2021-03-30       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.